中國匯融(01290.HK)盈喜:預計年度純利大幅上升3700%至4000%
格隆匯3月9日丨中國匯融(01290.HK)發佈公吿,截至2021年12月31日止年度,董事會預期該年度的收入將較上年度的收入大幅上升約39%至43%(2020年:人民幣2.598億元);及預期該年度的權益持有人應占利潤將較上年度的權益持有人應占利潤大幅上升約3700%至4000%(2020年:人民幣220萬元)。
公吿稱,以上該年度的收入增加主要歸因於集團供應鏈管理業務收入顯著增加,以及典當業務、商業保理業務、藝術品投資業務收入分別略有增加。以上該年度的權益持有人應占利潤增加主要歸因於2021年12月竣工的投資性物業中匯金融大廈公允價值變動,以及上述因素導致的收入增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.